Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 93,993.33% | 4.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 93,993.33% | 4.17% | |||
| Cost of Revenue | -0.42% | 1,407.06% | |||
| Gross Profit | 81.87% | -1,424.86% | |||
| SG&A Expenses | 20.31% | 18.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.50% | 13.74% | |||
| Operating Income | 62.52% | -13.74% | |||
| Income Before Tax | 65.65% | -15.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 65.65% | -15.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 65.65% | -15.90% | |||
| EBIT | 62.52% | -13.74% | |||
| EBITDA | 62.59% | -13.77% | |||
| EPS Basic | 65.72% | -15.62% | |||
| Normalized Basic EPS | 65.73% | -15.54% | |||
| EPS Diluted | 65.72% | -15.62% | |||
| Normalized Diluted EPS | 65.73% | -15.54% | |||
| Average Basic Shares Outstanding | 0.23% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||